One Year After Government Approval, The Spatz3 Adjustable Gastric Balloon Finds Success In Mexico And Along The U.S. Border

COFEPRIS, the Mexican Health authority, approved Spatz3 Adjustable Gastric Balloon

Feb 17, 2016, 09:57 ET from Spatz FGIA, Inc.

GREAT NECK, N.Y., Feb. 17, 2016 /PRNewswire/ -- Spatz FGIA, Inc., www.spatzmedical.com, makers of the Spatz3 Adjustable intragastric balloon, announces that, one year after official government approval, Spatz3 adjustable gastric balloons have met with higher than projected success and acceptance in Mexico. The Spatz3 adjustable gastric balloon provides an effective, reversible and less costly alternative to weight loss surgery for individuals who are overweight or obese. This is especially significant due to the high rates of obesity in Mexico. A recent national health survey found that 56% of the population of Mexico City is overweight or clinically obese.

Abraham Renner of Biomedics, Spatz partner in Mexico City, reported, "Up to now, most of the market has been private. However, we see a lot of potential in the public health system, since Mexico has one of the highest obesity rates in the world. In addition, with experienced bariatric physicians working in Mexico, US citizens can take advantage of the warm attention and affordable services offered by bariatric centers along Mexico's border with California, Arizona and Texas."

Dr. Jeffrey Brooks, Founder and CEO of Spatz FGIA, Inc. spoke about features that set the Spatz3 balloon apart from its competitors. "We have been quite encouraged by the rapid growth of our market share in Mexico in a relatively short span of time. Both doctors and patients alike appreciate the extra functions afforded by the Spatz3 adjustable balloon. As shown in the recently completed FDA trials, there was a 22% rate of early balloon extraction with the competing Orbera balloon, due to intolerance. The Spatz3 balloon offers the ability to change balloon volume to alleviate intolerance, thereby avoiding the necessity for early extraction. Furthermore, a second wave of weight loss, after midterm balloon volume expansion, is unique to the Spatz3 balloon." 

About Your Company: Spatz FGIA, Inc. is a medical device company that created the next generation gastric balloon for the worldwide obesity epidemic. Now available for commercial use in close to 40 countries, the company's flagship product, the Spatz3 Adjustable Balloon System®, offers a unique non-surgical solution for the overweight and obese. The 15-minute out-patient procedure reduces stomach capacity to give patients a feeling of satiety.

 

SOURCE Spatz FGIA, Inc.



RELATED LINKS

http://www.spatzmedical.com